Bondoc A, Golbar H M, Pervin M, Katou-Ichikawa C, Tanaka M, Izawa T, Kuwamura M, Yamate J
Laboratory of Veterinary Pathology, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, 1-58 Rinku-Ourai-Kita, Izumisano City, Osaka, 598-8531, Japan.
Cancer Microenviron. 2017 Dec;10(1-3):9-24. doi: 10.1007/s12307-017-0193-x. Epub 2017 Jun 16.
Tumor progression is often influenced by infiltration of myeloid cells; depending on the M1- or M2-like activation status, these cells may have either inhibitory or promoting effects on tumor growth. We investigated the properties of tumor-associated myeloid cells in a previously established homotransplantable amelanotic melanoma (RMM tumor line) in F344 rats. RMM tumor nodules were allowed to reach the sizes of 0.5, 1, 2 and 3 cm, respectively. Immunohistochemistry and flow cytometry was performed for macrophage markers CD68 and CD163, and for the antigen-presenting cell marker, MHC class II. Although no significant change was observed in the number of CD68 and CD163 macrophages during RMM progression, the number of MHC class II antigen-presenting cells was reduced in 3 cm nodules. Real-time RT-PCR of laser microdissection samples obtained from RMM regions rich in MHC class II cells demonstrated high expressions of M1-like factors: IFN-γ, GM-CSF and IL-12a. Furthermore, fluorescence-activated cell sorting, followed by real-time RT-PCR for CD11b MHC class II (myeloid antigen-presenting cells), CD11b CD163 (M2 type myeloid cells), CD11b CD80 (M1 type myeloid cells) and CD11b CD11c (dendritic cells) cells was performed. Based on the levels of inflammation- and tumor progression-related factors, MHC class II antigen-presenting cells showed polarization towards M1, while CD163 macrophages, towards M2. CD80 and CD11c myeloid cells did not show clear functional polarization. Our results provide novel information on tumor-associated myeloid cells in amelanotic melanoma, and may become useful in further research on melanoma immunity.
肿瘤进展常受髓样细胞浸润的影响;根据M1或M2样激活状态,这些细胞可能对肿瘤生长具有抑制或促进作用。我们在先前建立的F344大鼠同基因移植性无黑色素黑色素瘤(RMM肿瘤系)中研究了肿瘤相关髓样细胞的特性。使RMM肿瘤结节分别达到0.5、1、2和3厘米大小。对巨噬细胞标志物CD68和CD163以及抗原呈递细胞标志物MHC II类进行免疫组织化学和流式细胞术检测。尽管在RMM进展过程中CD68和CD163巨噬细胞数量未观察到显著变化,但在3厘米的结节中MHC II类抗原呈递细胞数量减少。对从富含MHC II类细胞的RMM区域获得的激光显微切割样本进行实时RT-PCR,结果显示M1样因子:IFN-γ、GM-CSF和IL-12a高表达。此外,进行了荧光激活细胞分选,随后对CD11b MHC II类(髓样抗原呈递细胞)、CD11b CD163(M2型髓样细胞)、CD11b CD80(M1型髓样细胞)和CD11b CD11c(树突状细胞)细胞进行实时RT-PCR。基于炎症和肿瘤进展相关因子的水平,MHC II类抗原呈递细胞向M1极化,而CD163巨噬细胞向M2极化。CD80和CD11c髓样细胞未显示出明显的功能极化。我们的结果提供了关于无黑色素黑色素瘤中肿瘤相关髓样细胞的新信息,可能有助于黑色素瘤免疫的进一步研究。